Results 11 to 20 of about 42,353 (227)

Collagen can selectively trigger a platelet secretory phenotype via glycoprotein VI. [PDF]

PLoS ONE, 2014
Platelets are not only central actors of hemostasis and thrombosis but also of other processes including inflammation, angiogenesis, and tissue regeneration.
Véronique Ollivier, Varouna Syvannarath, Angèle Gros, Amena Butt, Stéphane Loyau, Martine Jandrot-Perrus, Benoît Ho-Tin-Noé   +6 more
doaj   +3 more sources

ADPase CD39 Fused to Glycoprotein VI‐Fc Boosts Local Antithrombotic Effects at Vascular Lesions [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
BackgroundGPVI (Glycoprotein VI) is the essential platelet collagen receptor in atherothrombosis. Dimeric GPVI‐Fc (Revacept) binds to GPVI binding sites on plaque collagen. As expected, it did not increase bleeding in clinical studies.
Heidrun Degen, Oliver Borst, Melanie Ziegler, Ann‐Katrin Mojica Munoz, Janina Jamasbi, Britta Walker, Silvia Göbel, Julia Fassbender, Kristin Adler, Richard Brandl, Götz Münch, Reinhard Lorenz, Wolfgang Siess, Meinrad Gawaz, Martin Ungerer   +14 more
doaj   +2 more sources

Protease-activated receptors and glycoprotein VI cooperatively drive the platelet component in thromboelastography. [PDF]

J Thromb Haemost, 2023
Rudran T, Antoniak S, Flick MJ, Ginsberg MH, Wolberg AS, Bergmeier W, Lee RH.   +6 more
europepmc   +3 more sources

Efficacy of human epididymis protein-IV as potential lung disease biomarker in comparison to Krebs von den Lungen-VI glycoprotein and apoprotein A2 among systemic sclerosis patients [PDF]

Egyptian Rheumatology and Rehabilitation
Background Systemic sclerosis is a connective tissue disease of unknown etiology, characterized by vasculopathy, fibrosis, inflammation, and immune dysregulation that lead to widespread internal organs fibrosis, chronic ischemia, and subsequent end-stage
Alaa Mohammad El-Salawy, Hanaa Samy El-Banna, Manal Shawky Hussein, Mohamed Hosny Fouda, Rasha Ahmad Gaber, Rasha Youssef Hagag, Souzan Ezzat Gado   +6 more
doaj   +2 more sources

Genetic variation of platelet glycoprotein VI and the risk of venous thromboembolism [PDF]

Haematologica, 2020
Hanne Skille, Benedikte Paulsen, Kristian Hveem, Maiken E. Gabrielsen, Ben Brumpton, Kristian Hindberg, Olga V. Gran, Frits R. Rosendaal, Sigrid K. Brækkan, John-Bjarne Hansen   +9 more
doaj   +2 more sources

Glenzocimab does not impact glycoprotein VI-dependent inflammatory hemostasis

Haematologica, 2020
Soumaya Jadoui, Ophélie Le Chapelain, Véronique Ollivier, Ali Mostefa-Kara, Lucas Di Meglio, Sébastien Dupont, Angèle Gros, Mialitiana Solo Nomenjanahary, Jean-Philippe Desilles, Mikaël Mazighi, Bernhard Nieswandt, Stéphane Loyau, Martine Jandrot-Perrus, Pierre H Mangin, Benoit Ho-Tin-Noé   +14 more
doaj   +3 more sources

Soluble glycoprotein VI predicts abdominal aortic aneurysm growth rate and is a novel therapeutic target.

Blood
Benson TW, Pike MM, Spuzzillo A, Hicks SM, Ali S, Pham M, Mix DS, Brunner SI, Wadding-Lee C, Conrad KA, Russell HM, Jennings C, Coughlin TM, Aggarwal A, Lyden S, Mani K, Björck M, Wanhainen A, Bhandari R, Lipworth-Elliot L, Robinson-Cohen C, Caputo FJ, Shim S, Quesada O, Tourdot B, Edwards TL, Tranter M, Gardiner EE, Mackman N, Cameron SJ, Owens AP.   +30 more
europepmc   +3 more sources

Impaired Glycoprotein VI-Mediated Signaling and Platelet Functional Responses in CD45 Knockout Mice. [PDF]

Thromb Haemost, 2019
Inamdar VV, Kostyak JC, Badolia R, Dangelmaier CA, Manne BK, Patel A, Kim S, Kunapuli SP.   +7 more
europepmc   +3 more sources

Glycoprotein VI inhibitors: glenzocimab and EMA601 two inhibitory Fabs. [PDF]

Eur Heart J
Mangin PH, Jandrot-Perrus M.
europepmc   +3 more sources

Sequence-specific 2'-O-methoxyethyl antisense oligonucleotides activate human platelets through glycoprotein VI, triggering formation of platelet-leukocyte aggregates

Haematologica, 2021
Antisense oligonucleotides (ASO) are DNA-based, disease-modifying drugs. Clinical trials with 2'-O-methoxyethyl (2’MOE) ASO have shown dose- and sequence-specific lowering of platelet counts according to two phenotypes.
Martina H. Lundberg Slingsby, Prakrith Vijey, I-Ting Tsai, Harvey Roweth, Genevieve Couldwell, Adrian R. Wilkie, Hans Gaus, Jazana M. Goolsby, Ross Okazaki, Brooke E. Terkovich, John W. Semple, Jonathan N. Thon, Scott P. Henry, Padmakumar Narayanan, Joseph E. Italiano Jr.   +14 more
doaj   +1 more source